Breaking News

Sagent Pharma Names EVP Global Operations

February 26, 2016

Frank Harmon will take on the newly created position

Sagent Pharmaceuticals, a provider of pharmaceuticals to the hospital market, has named Frank Harmon as executive vice president, global operations. In this newly created role, Mr. Harmon will oversee Sagent's global operations including product development, R&D, manufacturing, supply chain, regulatory and global alliance management, with oversight support of quality assurance.

"Mr. Harmon joins Sagent at an exciting time as we begin to execute against our Triple E strategy which is focused on accelerating our growth and enhancing our operational performance,” said Allan Oberman, chief executive officer, Sagent. "Frank's extensive experience in pharmaceutical manufacturing and operations, with a proven history of success operating multiple injectable facilities, improving margins and managing complicated supply chains, will play an important role in accelerating our long-term growth trajectory and capitalizing on the favorable market opportunities that we see as critical to long-term value creation.”

Mr. Harmon has close to 40 years of pharmaceutical operations experience with companies including Fresenius Kabi, Cardinal Health, and Aventis-Behring (formerly Centeon LLC). Most recently, he served as vice president, operations of Nesher Pharmaceuticals, a wholly owned subsidiary of Zydus Pharmaceuticals, where he was responsible for all manufacturing and contract packaging operations for generic solid dose and oral liquid products. 

Related Packaging:

blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision